GREENLAND MINES LTD Gain (Loss) on Extinguishment of Debt
GREENLAND MINES LTD (GRML) reported Gain (Loss) on Extinguishment of Debt of -$448.80 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-08-17
- GREENLAND MINES LTD gain (loss) on extinguishment of debt for the quarter ending 2025-09-30 was -$2.76M.
- GREENLAND MINES LTD gain (loss) on extinguishment of debt for the quarter ending 2025-06-30 was -$331.55K.
- GREENLAND MINES LTD gain (loss) on extinguishment of debt for the quarter ending 2025-03-31 was -$117.26K.
- GREENLAND MINES LTD gain (loss) on extinguishment of debt for the quarter ending 2024-09-30 was -$84.56K.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 6 month as first filed | Gain (Loss) on Extinguishment of Debt 9 month |
|---|---|---|---|---|
| 2025-09-30 | -$2.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$3.09M derived: sum of 2 quarters · filed 2025-11-13 | -$448.80K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | -$331.55K 10-Q · filed 2025-08-18 | $2.31M 10-Q · filed 2026-08-17 | -$448.80K 10-Q · filed 2025-08-18 | |
| 2025-03-31 | -$117.26K 10-Q · filed 2025-05-15 | |||
| 2024-09-30 | -$84.56K 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |